Apremilast for the treatment of moderate‐to‐severe palmoplantar psoriasis: results from a double‐blind, placebo‐controlled, randomized study

Apremilast for the treatment of moderate‐to‐severe palmoplantar psoriasis: results from a... IntroductionPalmoplantar involvement in patients with psoriasis can severely impact quality of life and limit work productivity. Topical treatments generally have limited efficacy for moderate‐to‐severe palmoplantar psoriasis. Systemic treatments such as methotrexate, acitretin, tumour necrosis factor alpha (TNF‐α) inhibitors (etanercept, adalimumab and infliximab) and interleukin 17A or 12/23 inhibitors (secukinumab and ustekinumab) have been reported to be efficacious. However, their efficacy in palmoplantar psoriasis is usually lower than when they are used for psoriasis vulgaris. Only 30–40% of patients with moderate‐to‐severe palmoplantar psoriasis achieve a Palmoplantar Psoriasis Physician Global Assessment (PPPGA) of 0/1 after 12–16 weeks of treatment with biologics. There is a need for the development of novel treatments for palmoplantar psoriasis.Apremilast is an oral phosphodiesterase inhibitor, that is approved for the treatment of psoriasis and psoriatic arthritis. A post hoc analysis of palmoplantar data from three phase 2 and 3 studies conducted in patients with moderate‐to‐severe psoriasis vulgaris suggested that apremilast could be effective for the treatment of psoriasis involving palms and soles. However, this analysis included all patients presenting at least a moderate severity based on physician global assessment of palmoplantar disease regardless of the surface area involved with palmoplantar psoriasis at baseline. This study evaluates the efficacy http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of the European Academy of Dermatology & Venereology Wiley

Apremilast for the treatment of moderate‐to‐severe palmoplantar psoriasis: results from a double‐blind, placebo‐controlled, randomized study

Loading next page...
 
/lp/wiley/apremilast-for-the-treatment-of-moderate-to-severe-palmoplantar-7Gml0hewVF
Publisher
Wiley Subscription Services, Inc., A Wiley Company
Copyright
Copyright © 2018 European Academy of Dermatology and Venereology
ISSN
0926-9959
eISSN
1468-3083
D.O.I.
10.1111/jdv.14647
Publisher site
See Article on Publisher Site

Abstract

IntroductionPalmoplantar involvement in patients with psoriasis can severely impact quality of life and limit work productivity. Topical treatments generally have limited efficacy for moderate‐to‐severe palmoplantar psoriasis. Systemic treatments such as methotrexate, acitretin, tumour necrosis factor alpha (TNF‐α) inhibitors (etanercept, adalimumab and infliximab) and interleukin 17A or 12/23 inhibitors (secukinumab and ustekinumab) have been reported to be efficacious. However, their efficacy in palmoplantar psoriasis is usually lower than when they are used for psoriasis vulgaris. Only 30–40% of patients with moderate‐to‐severe palmoplantar psoriasis achieve a Palmoplantar Psoriasis Physician Global Assessment (PPPGA) of 0/1 after 12–16 weeks of treatment with biologics. There is a need for the development of novel treatments for palmoplantar psoriasis.Apremilast is an oral phosphodiesterase inhibitor, that is approved for the treatment of psoriasis and psoriatic arthritis. A post hoc analysis of palmoplantar data from three phase 2 and 3 studies conducted in patients with moderate‐to‐severe psoriasis vulgaris suggested that apremilast could be effective for the treatment of psoriasis involving palms and soles. However, this analysis included all patients presenting at least a moderate severity based on physician global assessment of palmoplantar disease regardless of the surface area involved with palmoplantar psoriasis at baseline. This study evaluates the efficacy

Journal

Journal of the European Academy of Dermatology & VenereologyWiley

Published: Jan 1, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off